| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
NEWS |
NCCN Guidelines Advocate Wider Use of Colony-Stimulating Factor
| The first 10% of the full text of this article appears below. |
Citing data from a recent major clinical trial, the National Comprehensive Cancer Network (NCCN) has issued guidelines advocating the use of colony-stimulating factor (CSF) to prevent febrile neutropenia in patients with a 20% risk of developing the condition. Up to now, guidelines from the American Society of Clinical Oncology (ASCO) and others have recommended CSFs only for patients at a 40% or higher risk.
The new guidelines have the potential to affect supportive care for hundreds of thousands of chemotherapy patients. Amgen, which makes the two most commonly used CSFs in the United States, filgrastim (Neupogen) and pegfilgrastim (Neulasta), estimates that about 300,000 patients now take the drugs annually.
The trial that played a
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. G. C. Brain, T. Bachelot, and D. Serin Life-threatening Complications From Doxorubicin-Docetaxel Chemotherapy for Breast Cancer--Reply JAMA, November 2, 2005; 294(17): 2166 - 2167. [Full Text] [PDF]
|
|